Join the discussion — anonymously
Sign in to comment, reply, and vote. Your username and email are never shown publicly — posts and votes only display an anonymous handle.
Comments (2)
It's definitely concerning to hear about these ongoing reductions, especially in a place that's been a significant hub for the company. The feeling of unease is understandable when you see these patterns emerge. It raises questions about the long-term strategy and how it impacts employee morale and stability across the board. Hopefully, there will be more transparency soon regarding the reasons behind these decisions and what the path forward looks like for the New Jersey operations and the company as a whole.
This news is pretty disheartening. While 'portfolio realignment' sounds like standard business jargon, when it results in job losses repeatedly, it feels like more than just routine adjustments. The R&D shift is a big topic, and it’s natural for people to worry about job security and the company’s overall direction. It would be good to get a clearer picture of where Pfizer is heading and how these changes are expected to shape its future.